These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 16410744

  • 1. Genetic alterations in primary glioblastomas in Japan.
    Fukushima T, Favereaux A, Huang H, Shimizu T, Yonekawa Y, Nakazato Y, Ohagki H.
    J Neuropathol Exp Neurol; 2006 Jan; 65(1):12-8. PubMed ID: 16410744
    [Abstract] [Full Text] [Related]

  • 2. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
    Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, Ohgaki H.
    J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
    [Abstract] [Full Text] [Related]

  • 3. Genetic pathways to glioblastoma: a population-based study.
    Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P.
    Cancer Res; 2004 Oct 01; 64(19):6892-9. PubMed ID: 15466178
    [Abstract] [Full Text] [Related]

  • 4. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U.
    Acta Neuropathol; 2001 Apr 01; 101(4):311-20. PubMed ID: 11355302
    [Abstract] [Full Text] [Related]

  • 5. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H, Kleihues P.
    J Neuropathol Exp Neurol; 2005 Jun 01; 64(6):479-89. PubMed ID: 15977639
    [Abstract] [Full Text] [Related]

  • 6. Age-dependent prognostic effects of genetic alterations in glioblastoma.
    Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 1):228-33. PubMed ID: 14734474
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Boström J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP, Reifenberger G.
    Cancer Res; 1998 Jan 01; 58(1):29-33. PubMed ID: 9426052
    [Abstract] [Full Text] [Related]

  • 9. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
    Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerdá-Nicolas M, Lopez-Gines C.
    Neuropathology; 2010 Aug 01; 30(4):392-400. PubMed ID: 20051017
    [Abstract] [Full Text] [Related]

  • 10. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H.
    J Neuropathol Exp Neurol; 1998 Jul 01; 57(7):684-9. PubMed ID: 9690672
    [Abstract] [Full Text] [Related]

  • 11. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
    Hegi ME, zur Hausen A, Rüedi D, Malin G, Kleihues P.
    Int J Cancer; 1997 Sep 26; 73(1):57-63. PubMed ID: 9334810
    [Abstract] [Full Text] [Related]

  • 12. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.
    Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H.
    Lab Invest; 2000 Jan 26; 80(1):65-72. PubMed ID: 10653004
    [Abstract] [Full Text] [Related]

  • 13. Genetic pathways to primary and secondary glioblastoma.
    Ohgaki H, Kleihues P.
    Am J Pathol; 2007 May 26; 170(5):1445-53. PubMed ID: 17456751
    [Abstract] [Full Text] [Related]

  • 14. Independent molecular development of metachronous glioblastomas with extended intervening recurrence-free interval.
    Martinez R, Schackert HK, von Kannen S, Lichter P, Joos S, Schackert G.
    Brain Pathol; 2003 Oct 26; 13(4):598-607. PubMed ID: 14655763
    [Abstract] [Full Text] [Related]

  • 15. Genetic profile of gliosarcomas.
    Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H.
    Am J Pathol; 2000 Feb 26; 156(2):425-32. PubMed ID: 10666371
    [Abstract] [Full Text] [Related]

  • 16. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
    Schmidt EE, Ichimura K, Goike HM, Moshref A, Liu L, Collins VP.
    J Neuropathol Exp Neurol; 1999 Nov 26; 58(11):1170-83. PubMed ID: 10560660
    [Abstract] [Full Text] [Related]

  • 17. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
    Liu W, James CD, Frederick L, Alderete BE, Jenkins RB.
    Cancer Res; 1997 Dec 01; 57(23):5254-7. PubMed ID: 9393744
    [Abstract] [Full Text] [Related]

  • 18. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW.
    Brain Pathol; 2000 Apr 01; 10(2):249-59. PubMed ID: 10764044
    [Abstract] [Full Text] [Related]

  • 19. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.
    JAMA; 2009 Jul 15; 302(3):276-89. PubMed ID: 19602687
    [Abstract] [Full Text] [Related]

  • 20. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W, Debiec-Rychter M, Liberski PP.
    Pol J Pathol; 1998 Jul 15; 49(4):267-71. PubMed ID: 10323080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.